New Jersey's federal courts are in the midst of a surge in patent litigation, driven by pharmaceutical companies' claims of infringement against generic-drug producers.
Plaintiffs filed seven patent suits in the District of New Jersey from May 20-26, representing a major escalation when compared with the average rate of one new patent suit per week. And the surge continued in the period from May 26-30, when another three patent suits were filed.
All but one of the 10 cases were brought by holders of drug patents seeking to stop the production of generic versions of their products.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Charles Toutant
Charles Toutant is a litigation writer for the New Jersey Law Journal.
